AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$TLRY

Tilray Brands Q1 Revenue Rises 23% to $257.1 Million as Beverage Sales Surge Following BrewDog Acquisition

Tilray Brands reported a 23% revenue increase to $257.1M for Q1 2027, driven by an 82% surge in beverage sales following the BrewDog acquisition. Gross profit rose 35% to $77.5M, but adjusted EBITDA declined. Cannabis revenue fell, while debt was reduced by $42M. The company maintained its adjusted EBITDA guidance of $68M-$75M for the year.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 12:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray Brands Q1 Revenue Rises 23% to $257.1 Million as Beverage Sales Surge Following BrewDog Acquisition — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TLRYNeutralMed
01

Why it matters

Earnings release with mixed results; revenue growth offsets loss, guidance unchanged.

02

Market read

Tilray's earnings may influence cannabis sector sentiment and beverage‑related growth narratives.

03

What to watch

Debt reduction and strong cash position may provide runway for strategic acquisitions.

Relevance 8/10Novelty 7/10Timing: after-hours

Background

Tilray Brands, a US‑listed cannabis and beverage company, disclosed its first‑quarter 2027 financials following the BrewDog acquisition.

Company-level read

Ticker impact

$TLRYNeutralHigh confidence
Context

Tilray Brands reported Q1 2027 results with 23% revenue growth, an $40M net loss and reaffirmed full-year adjusted EBITDA guidance.

Expected impact

likely modest pressure as investors weigh loss versus revenue growth

Evidence & confidence

Revenue beat is positive, but a $40M loss and declining adjusted EBITDA may limit upside; guidance unchanged reduces surprise.

Market effects

Sector

Beverage segment growth may boost cannabis‑adjacent consumer‑product stocks.

Regional

North American cannabis and beverage markets see modest attention.

Global

Limited; primarily impacts Tilray and peers in the cannabis sector.

Counterpoint

What could challenge this read

The revenue boost from BrewDog could signal a longer‑term upside if margins improve.

Key entities

  • Company
    Tilray Brands, Inc.

    US‑listed cannabis and beverage producer (NASDAQ:TLRY).

  • Company
    BrewDog

    Acquired beverage brand contributing to Tilray's revenue surge.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min